Dynamic Advisor Solutions LLC Sells 1,013 Shares of Sanofi (NASDAQ:SNY)

Dynamic Advisor Solutions LLC reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 1.8% during the third quarter, HoldingsChannel reports. The firm owned 55,831 shares of the company’s stock after selling 1,013 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Sanofi were worth $3,218,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of SNY. Barrow Hanley Mewhinney & Strauss LLC raised its stake in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares during the last quarter. Magnetar Financial LLC grew its holdings in shares of Sanofi by 1,153.1% in the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after acquiring an additional 2,306,286 shares during the period. Bank of New York Mellon Corp increased its position in Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the last quarter. Mondrian Investment Partners LTD lifted its holdings in Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in Sanofi by 3,440.6% in the first quarter. BNP Paribas Financial Markets now owns 1,033,549 shares of the company’s stock worth $50,230,000 after purchasing an additional 1,004,358 shares during the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Up 0.2 %

Shares of NASDAQ:SNY opened at $54.85 on Wednesday. The stock has a 50 day moving average of $55.58 and a 200 day moving average of $51.19. The company has a market cap of $138.92 billion, a PE ratio of 27.56, a price-to-earnings-growth ratio of 1.58 and a beta of 0.60. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.95 earnings per share. As a group, equities research analysts expect that Sanofi will post 4.26 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.